SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Turner will provide his perspective on adopting personalized medicine and the potential ROI at the Duke Center for Personalized Medicine Symposium on March 29 in Durham, NC.
News | 03. 28. 2012
Turner will provide his perspective on adopting personalized medicine and the potential ROI at the Duke Center for Personalized Medicine Symposium on March 29 in Durham, NC.
